Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084

Roobol, 2009, Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC), Eur Urol, 56, 584, 10.1016/j.eururo.2009.07.018

Gotzsche, 2009, Screening for breast cancer with mammography, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD001877.pub3

Hewitson, 2008, Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update, Am J Gastroenterol, 103, 1541, 10.1111/j.1572-0241.2008.01875.x

Nelson, 2009, Screening for breast cancer: an update for the U.S. Preventive Services Task Force, Ann Intern Med, 151, 727, 10.7326/0003-4819-151-10-200911170-00009

Towler, 1998, A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult, BMJ, 317, 559, 10.1136/bmj.317.7158.559

Andriole, 2009, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 360, 1310, 10.1056/NEJMoa0810696

Sandblom, 2004, Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden, Eur Urol, 46, 717, 10.1016/j.eururo.2004.08.011

Kjellman, 2009, 15-year followup of a population based prostate cancer screening study, J Urol, 181, 1615, 10.1016/j.juro.2008.11.115

Labrie, 2004, Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial, Prostate, 59, 311, 10.1002/pros.20017

Ilic, 2007, Screening for prostate cancer: A Cochrane systematic review, Cancer Causes Control, 18, 279, 10.1007/s10552-006-0087-6

Bergdahl, 2009, Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees, Cancer, 115, 5672, 10.1002/cncr.24680

1999

Rafferty, 2000, Reference reagents for prostate-specific antigen (PSA): establishment of the First International Standards for free PSA and PSA (90:10), Clin Chem, 46, 1310, 10.1093/clinchem/46.9.1310

De Koning, 2003, Determining the cause of death in randomized screening trial(s) for prostate cancer, BJU Int, 92, 71, 10.1111/j.1465-5101.2003.04402.x

Grambsch, 1994, Proportional hazards tests and diagnostics based on weighted residuals, Biometrika, 81, 515, 10.1093/biomet/81.3.515

Aalen, 1978, Nonparametric inference for a family of counting processes, Ann Stat, 6, 701, 10.1214/aos/1176344247

Grubb, 2008, Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial, BJU Int, 102, 1524, 10.1111/j.1464-410X.2008.08214.x

Tornblom, 2004, Lead time associated with screening for prostate cancer, Int J Cancer, 108, 122, 10.1002/ijc.11554

Albertsen, 2005, 20-year outcomes following conservative management of clinically localized prostate cancer, JAMA, 293, 2095, 10.1001/jama.293.17.2095

Bartsch, 2008, Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality, BJU Int, 101, 809, 10.1111/j.1464-410X.2008.07502.x

Brindle, 2006, Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK, BJU Int, 98, 777, 10.1111/j.1464-410X.2006.06401.x

Carlsson, 2007, Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - results from a prospective, population-based, randomised study, Eur J Cancer, 43, 2109, 10.1016/j.ejca.2007.06.002

Miller, 2002, The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years, Ann Intern Med, 137, 305, 10.7326/0003-4819-137-5_Part_1-200209030-00005

Miller, 2000, Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years, J Natl Cancer Inst, 92, 1490, 10.1093/jnci/92.18.1490

Nystrom, 2002, Long-term effects of mammography screening: updated overview of the Swedish randomised trials, Lancet, 359, 909, 10.1016/S0140-6736(02)08020-0

Moss, 2006, Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial, Lancet, 368, 2053, 10.1016/S0140-6736(06)69834-6

Tabar, 1995, Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial, Cancer, 75, 2507, 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H

Shapiro, 1982, Ten- to fourteen-year effect of screening on breast cancer mortality, J Natl Cancer Inst, 69, 349

Frisell, 1997, Followup after 11 years–update of mortality results in the Stockholm mammographic screening trial, Breast Cancer Res Treat, 45, 263, 10.1023/A:1005872617944

Bjurstam, 2003, The Gothenburg Breast Screening Trial, Cancer, 97, 2387, 10.1002/cncr.11361

Kronborg, 2004, Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds, Scand J Gastroenterol, 39, 846, 10.1080/00365520410003182

Lindholm, 2008, Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer, Br J Surg, 95, 1029, 10.1002/bjs.6136

Mandel, 1999, Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood, J Natl Cancer Inst, 91, 434, 10.1093/jnci/91.5.434

Scholefield, 2002, Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial, Gut, 50, 840, 10.1136/gut.50.6.840

Atkin, 2010, Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial, Lancet, 375, 1624, 10.1016/S0140-6736(10)60551-X

Albertsen, 2009, The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis, Urology, 75, 399, 10.1016/j.urology.2009.08.078

Khatami, 2007, PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section, Int J Cancer, 120, 170, 10.1002/ijc.22161